AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price target decreased by research analysts at Truist Financial from $30.00 to $20.00 in a report released on Wednesday, Benzinga reports. The ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming trial results in 2025-2026.

AnaptysBio said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AnaptysBio has released its third quarter 2024 financial results, highlighting significant progress in its clinical pipeline and financial performance.